FDA, EMA put a star CAR-T from blue­bird and Cel­gene on the VIP list

Dur­ing the last AS­CO blue­bird bio and its part­ners at Cel­gene an­gled in­to cen­ter stage with an up­date on their BC­MA-tar­get­ing CAR-T drug bb2121 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.